ArticleDiscover medicine2025
Delayed cerebral ischaemia after subarachnoid haemorrhage: pathophysiology, diagnosis and neurotherapeutic opportunities.
Article in Discover medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Effects of Milrinone Systemic Administration on Cerebral Perfusion as Measured with Computed Tomography in Aneurysmal Subarachnoid Hemorrhage Patients.Neurocritical care · 2026Observational
- Active Cerebrospinal Fluid Exchange Versus External Ventricular Drainage in IVH and SAH: A Meta-Analysis.Stroke (Hoboken, N.J.) · 2026Article
- Subarachnoid hemorrhage: epidemiology, risk factors, pathogenesis, and clinical therapies.Molecular biomedicine · 2026Review
- Aneurysmal subarachnoid hemorrhage-risk score-impact of pre-existing cardiovascular risk factors on functional patient outcomes.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed cerebral ischaemia is a serious complication following aneurysmal subarachnoid haemorrhage (aSAH), leading to poor outcomes. This review discusses the pathophysiology of DCI, focusing on the role of cerebral vasospasm, reduction in the cerebral blood flow and the factors that affect the vasospasm and DCI. Biomarkers play a crucial role in DCI's recognition, risk stratification, and outcome prediction. Goal-directed management aims to ameliorate the reduced cerebral blood flow, restore circulation and substrate delivery, and protect neurons. These strategies include the maintenance of cerebral blood flow and restoring substrate delivery by optimising oxygenation and maintaining normoglycaemia. Neuroprotective agents, such as calcium channel blockers like nimodipine, play a crucial role by reducing neuronal calcium influx and improving collateral circulation. Multimodal monitoring, incorporating techniques like transcranial Doppler, continuous EEG, and intracranial pressure monitoring, is essential for guiding treatment decisions and evaluating the efficacy of interventions. In the future, research should focus on a comprehensive approach to DCI management with pharmacological interventions and individualised treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.